Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, speculates on the future of biosimilars

Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, offers opinion on whether biosimilars are living up to their estimated cost savings

Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, comments on recent criticisms surrounding biosimilars

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, offers opinion on the most important critical success factors when adopting a new payment model

Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, reflects on social determinants of health and considers how an oncology practice can remain efficient and sensitive to patients who have just received a cancer diagnosis

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, discusses the impact of consolidation on the delivery of cancer care and on alterative payment models (APMs)

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, speculates on the future of alternative payment models (APMs) and explains how a practice can determine which APMs are most appropriate to pursue

Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, offers advice to oncology practices looking to succeed in today's landscape of cancer care

Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, regarding the impact of consolidation on the delivery of cancer care

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, considers how the concepts of value and quality may vary across community oncology practices

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, compares and contrasts the definition of value and quality as it relates to cancer care

Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, discusses some of the best practices for oncology practices to help reduce costs and maximize savings

Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, provides perspective on some of the biggest challenges currently facing oncology practices

Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, considers the progress being made at the community level in providing cancer patients with access to innovative therapies and quality of care while reducing cost

Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, offers a case example of how real-world evidence and health economics outcomes research (HEOR) have made an impact on the quality and cost of cancer care at Tennessee Oncology

Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, elaborates on how health economics outcomes research (HEOR) may be used in conjunction with artificial intelligence and/or real-world evidence

Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, considers how health economics and outcomes research (HEOR) data influences payer decisions

Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, explains the role of health economics outcomes research (HEOR) as it contributes to value-based care

Jonathan E. Levitt, Esq., Co-Founding Partner, Frier Levitt, considers how pharmacy benefit manager (PBM) behaviors are changing as a result of the COVID-19 pandemic

Jonathan E. Levitt, Esq., Co-Founding Partner, Frier Levitt, offers opinion on PBM consolidation and the changing dynamics of cancer care

Jonathan E. Levitt, Esq., Co-Founding Partner, Frier Levitt, explains how copay aggregators differ across PBMs

Jonathan E. Levitt, Esq., Co-Founding Partner, Frier Levitt, considers the experience of hematology/oncology groups who are unable to enter into a PBM network

Jonathan E. Levitt, Esq., Co-Founding Partner, Frier Levitt, explains how DIR fees impact practice costs and efficiencies

Jonathan E. Levitt, Esq., Co-Founding Partner, Frier Levitt, discusses the state of payer mandates for white bagging and brown bagging

Sara Riordan, Senior Director, Medical Education, OncoCyte Corporation, President, National Society of Genetic Counselors, discusses the role of genetic counselors as part of the multidisciplinary cancer team

Sara Riordan, Senior Director, Medical Education, OncoCyte Corporation, President, National Society of Genetic Counselors, offers opinion on why it is important to conduct genetic signature and biomarker testing in early-stage cancer patients

Sara Riordan, Senior Director, Medical Education, OncoCyte Corporation, President, National Society of Genetic Counselors, explains how genetic signature and biomarker tests are being used in the management of early-stage cancers

Sara Riordan, Senior Director, Medical Education, OncoCyte Corporation, President, National Society of Genetic Counselors, elaborates on the unmet needs in biomarker testing

Dr. Wilfong, EVP, Value Based Care & Quality Programs, Texas Oncology, Payment Reform Co-Chair, COA, discusses key takeaways from the 2021 Virtual Community Oncology Conference

Dr. Wilfong, EVP, Value Based Care & Quality Programs, Texas Oncology, Payment Reform Co-Chair, COA, regarding the impact of geographic location on the quality and delivery of cancer care

Dr. Wilfong, EVP, Value Based Care & Quality Programs, Texas Oncology, Payment Reform Co-Chair, COA, considers the impact of the Oncology Care First (OCF) model on cancer practices

Dr. Wilfong, EVP, Value Based Care & Quality Programs, Texas Oncology, Payment Reform Co-Chair, COA, offers opinion on the success factors for new payment reform models

Dr. Wilfong, EVP, Value Based Care & Quality Programs, Texas Oncology, Payment Reform Co-Chair, COA, speculates on the future of oncology medical homes

Dr. Kapur, Hematology/Oncology, Eastern Connecticut Hematology & Oncology, explains why Eastern Connecticut Hematology & Oncology eventually decided to give up their independence and join OneOncology

Dr. Kapur, Hematology/Oncology, Eastern Connecticut Hematology & Oncology, describes how OneOncology has welcomed his group and impressive cancer treatment resources

Dr. Kapur, Hematology/Oncology, Eastern Connecticut Hematology & Oncology, provides thoughts on early impressions of CMMI and the Oncology Care First (OCF) model

Dr. Kapur, Hematology/Oncology, Eastern Connecticut Hematology & Oncology, expresses thoughts on OCM reducing the cost of care and describes whether quality has suffered or improved because of it

Dr. Brooks, Medical Oncologist/Hematologist, Arizona Blood and Cancer Specialists, offers advantages and disadvantages of joining a large oncology group

Dr. Brooks, Medical Oncologist/Hematologist, Arizona Blood and Cancer Specialists, advises oncology practices that are considering whether to stay independent or to join a larger group of oncologists

Dr. Brooks, Medical Oncologist/Hematologist, Arizona Blood and Cancer Specialists, describes how OneOncology has welcomed his group and impressive resources that help treat cancer patients

Dr. Schleicher, Medical Oncologist, Tennessee Oncology, provides examples of how aligning incentives has improved the quality of cancer care delivery while reducing the overall cost of care

Dr. Schleicher, Medical Oncologist, Tennessee Oncology, describes how the cost of drugs are impacting the effectiveness of alternative payment models that oncology practices participate in

Dr. Blau, Medical Director, Northwest Medical Specialties, provides examples of how applied informatics are being incorporated into the management of cancer patients today

Dr. Blau, Medical Director, Northwest Medical Specialties, on how artificial intelligence is improving cancer care, especially in predicting high risk cancer patients

Dr. Blau, Chief Operations Officer, Northwest Medical Specialties, expounds upon maintaining quality care with non-clinical staff working remotely and steps being taken to aid in this situation

Kathy Oubre, Chief Operations Officer, describes robotic process automation and how it is helping with prior authorization in her practice

Kathy Oubre, Chief Operations Officer, details how developing tailored patient education in her practice has enhanced the patient/provider relationship

Kathy Oubre, Chief Operations Officer, Pontchartrain Cancer Center, considers the predicted surge to come in cancer patients after the COVID-19 pandemic ends

Kathy Oubre, Chief Operations Officer, Pontchartrain Cancer Center, offers best practices and/or new programs being implemented to safely treat patients during the COVID-19 pandemic

Dr. Patt, Executive Vice President, Texas Oncology, describes how applied informatics (ie A.I., big data) is being incorporated into the management of cancer patients today

Dr. Patt, Executive Vice President, Texas Oncology, expounds on the improvement of cancer care via artificial intelligence, especially in predicting high risk cancer patients

Dr. Patt, Executive Vice President, Texas Oncology, offers opinion on whether embracing informatics is worth the financial investment

Dr. Patton, CEO, Tennessee Oncology, expounds upon maintaining quality care with non-clinical staff working remotely and steps being taken to aid in this situation

Dr. Patton, CEO, Tennessee Oncology, anticipates whether small and rural practices will be able to stay afloat during the pandemic or if they are in danger of closing due to lack of resources

Dr. Patton, CEO, Tennessee Oncology, describes his care team's strengths as a result of the pandemic and habits to continue post pandemic

Dr. Patton, CEO, Tennessee Oncology, provides thoughts regarding the future of cancer care amidst a national crisis such as the COVID-19 pandemic and providing quality cancer care across the country

Dr. Patton, CEO, Tennessee Oncology, recalls big barriers to overcome when treating patients with cancer during the COVID-19 pandemic

Steven D'Amato, Executive Director, New England Cancer Specialists, on the adoption of telemedicine and its impact on the patient/provider relationship

Steven D'Amato, Executive Director, New England Cancer Specialists, describes best practices and/or new programs being adopted to safely treat patients during the COVID-19 pandemic

Steven D'Amato, Executive Director, New England Cancer Specialists, on his team's strength as a result of the pandemic and habits to continue post pandemic

Alti Rahman, Practice Administrator, Oncology Consultants, shares how robotic process automation is aiding with prior authorizations in his oncology practice

Alti Rahman, Practice Administrator, Oncology Consultants, offers an assessment of prior authorizations during the COVID-19 pandemic

Alti Rahman, Practice Administrator, Oncology Consultants, explains the adoption of telemedicine in his practice and reimbursement expectations

Nick Recker, President, Path Forward, describes the effectiveness of interoperability between telehealth platforms and oncology EMRs

Nick Recker, President, Path Forward, explains how successful oncology practices integrate telehealth as we emerge from the COVID-19 pandemic

Nick Recker, President, Path Forward, shares issues facing practices as they rush to integrate telehealth into practice operations

Nick Recker, President, Path Forward, describes the role of telehealth has played for healthcare providers in this current COVID-19 pandemic

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, describes the most common mistakes that practices make when coding for oncology treatment and services

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, expands on the practice coding problem and repercussions of improper coding

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, recommends best practices regarding proper coding for oncology practices

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, illustrates how practices are dealing with incorporating the new CMS telehealth/telemedicine codes in the midst of the COVID-19 pandemic

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, shares concerns on the coding changes coming in 2021 and the impact they may have on community oncology

Antonio Ciccia, Chief Stategy Officer, 3 Axis Advisors, expresses advantages Pharmacy Benefit Managers may bring to the healthcare system

Antonio Ciaccia, Chief Stategy Officer, 3 Axis Advisors, demonstrates how Pharmacy Benefit Managers are gaming the healthcare system

Antonio Ciaccia, Chief Strategy Officer, 3 Axis Advisors, explains how smaller pharmacies are able to compete with Pharmacy Benefit Managers and how they are being priced out

Antonio Ciaccia, Chief Strategy Officer, 3 Axis Advisors, on changes that need to be made on a national level that would bring Pharmacy Benefit Managers (PBMs) more in line with the interests of cancer patients and payers

Dr. Dietrich, Assistant Professor of Internal Medicine and Attending Physician, Orlando/Florida Hospital Cancer Institute, provides thoughts on how socioeconomic factors affect on access to Comprehensive Genomic Profiling (CGP) tests and subsequent decision making

Dr. Dietrich, Assistant Professor of Internal Medicine and Attending Physician, Orlando/Florida Hospital Cancer Institute, offers resources, such as molecular tumor boards, to aid in decision making after receiving Comprehensive Genomic Profiling (CGP) test results

Dr. Dietrich, Assistant Professor of Internal Medicine and Attending Physician, Orlando/Florida Hospital Cancer Institute, shares concerns about the validity of Comprehensive Genomic Profiling (CGP) tests and how this weighs into decision making for cancer patients

Dr. Dietrich, Assistant Professor of Internal Medicine and Attending Physician, Orlando/Florida Hospital Cancer Institute, explains who orders a Genomic Profiling (CPG) test in the community oncology settings and timelines of test results

Dr. Dietrich, Assistant Professor of Internal Medicine and Attending Physician, Orlando/Florida Hospital Cancer Institute, describes a Comprehensive Genomic Profiling (CGP) test, when it should be ordered, the information the results of the test provides

Dr. Patel, Chief Executive Officer, Carolina Blood and Cancer Care Associates, COA Payment Reform Co-Chair, recalls his practice's adaption to OCM 1.0 and taking it to the next step and adapting OCM 2.0

Dr. Patel, Chief Executive Officer, Carolina Blood and Cancer Care Associates, updates us on the stance of OCM 2.0 as of the annual COA meeting 2020

Dr. Patel, Chief Executive Officer, Carolina Blood and Cancer Care Associates, COA Payment Reform Co-Chair, provides examples of how aligning incentives has improved the quality of cancer care delivery while reducing the overall cost of care

Dr. Patel, Chief Executive Officer, Carolina Blood and Cancer Care Associates, COA Payment Reform Co-Chair, expresses early impressions of CMMI and the Oncology Care First (OCF) model

Thomas Sonderberg, Project Management Consultant, Evive, expresses opinion on components of care that should be essential for employers to consider as part of their comprehensive coverage of their employees

Thomas Sonderberg, Project Management Consultant, Evive, explains the needs of small to midsize employers compared with large employers that have more leverage when creating contracts

Thomas Sonderberg, Project Management Consultant, Evive, provides concerns and shortcomings of an employer coverage of cancer care and also the good news in cancer care

Thomas Sonderberg, Project Management Consultant, Evive, describes the scope of cancer care cost to an employer and how the cost of cancer care coverage varies by the types of employer

Kathy Oubre, Chief Operations Officer, Pontchartrain Cancer Center, shares opinion on whether cancer patients can be given home infusions of cancer treatments during the COVID-19 pandemic

Dr. Schleicher, Medical Oncologist, Tennessee Oncology, shares early impressions of CMMI and the Oncology Care First (OCF) model

Dr. Kapur, Hematology/Oncology, Eastern Connecticut Hematology Oncology, expresses changes in Eastern Connecticut Hematology Oncology amidst the COVID-19 pandemic

Dr. Blau, Medical Director, Northwest Medical Specialties, describes her care team's strength while embracing new communications and technology in the midst of the COVID-19 pandemic

Steven D'Amato, Executive Director, New England Cancer Specialists, on maintaining quality of care with non-clinical staff currently working remotely and steps steps being taken to support this situation

Dr. Patton, CEO, Tennessee Oncology, elaborates on critical success factors for providing quality cancer care during the COVID-19 pandemic

Dr. Patt, Executive Vice President, Texas Oncology, explains how informatics work with physicians to aid in treatment decision making at the point of care

Thomas Sonderberg, Project Management Consultant, Evive, describes challenges that employers face managing cancer care costs and the price of drugs

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, expounds on new services and associated codes that are important in the era of payment reform

Alti Rahman, Practice Administrator, Oncology Consultants, shares examples of best practices and/or new programs that his oncology practice has adopted in order to safely treat patients with cancer during the COVID-19 pandemic

Nick Recker, President, Path Forward, comments on security issues related to rapid adoption of Telehealth in oncology practices

Antonio Ciccia, Chief Strategy Officer, 3 Axis Advisors, describes pitfalls oncology practices need to know when prescribing a specialty cancer drug at a Pharmacy Benefit Managers-owned pharmacy

Dr. Dietrich, Assistant Professor of Internal Medicine and Attending Physician, Orlando/Florida Hospital Cancer Institute, provides examples of how the results of genetic profile tests are used when making decisions on cancer patient care.

Dr. Patel, Chief Executive Office, Carolina Blood and Cancer Associates, COA Payment Reform Chair, describes whether quality of care has suffered or improved as OCM reduces the cost of cancer care

Dr. Vacirca, CEO, New York Cancer & Blood Specialists, Director, OneOncology, discusses the capabilities of OneOncology's IT system

Dan Wygal, Executive Director, Contract and Channel Strategy, AstraZeneca, offers opinion on how benefit design and value based contracting might make cancer drugs more affordable

Dr. Vacirca, CEO, New York Cancer & Blood Specialists, Director, OneOncology, explains the synergy between three cancer centers that make up OneOncology

Dan Wygal, Executive Director, Contract and Channel Strategy, AstraZeneca, explains what AstraZeneca is doing to help make cancer drugs more accessible for patients

Dr. Vacirca, CEO, New York Cancer & Blood Specialists, Director, OneOncology, explains why OneOncology is a unique practice model and outlines the key drivers of success moving forward

Dan Wygal, Executive Director, Contract and Channel Strategy, AstraZeneca, discusses value-based contracting in oncology

Dr. Vacirca, CEO, New York Cancer & Blood Specialists, Director, OneOncology, describes some of the novel practice models presented at the 2019 Community Oncology Alliance Annual Conference

Jax Zummo, Sr. Director, Corporate Affairs, Lilly Oncology, outlines some of the concerns with value-based contracting

Jax Zummo, Sr. Director, Corporate Affairs, Lilly Oncology, explains the function of value-based contracting

Jax Zummo, Sr. Director, Corporate Affairs, Lilly Oncology, considers how the pharmaceutical industry is helping community oncology thrive

Dr. Schwartzberg, Chief Medical Officer, OneOncology, Medical Director, West Clinic, explains the key drivers of success for OneOncology

Dr. Schuh, Assistant Professor of Family Medicine, Palliative Medicine, Pharmacy, Mayo Clinic Florida, discusses advances and updates in integrative medicine of which pharmacists should be aware

Robin Shah, Chief Development and Chief Marketing Officer, OneOncology, considers whether OneOncology is poised for growth and open to expanding into other markets

Dr. Schwartzberg, Chief Medical Officer, OneOncology, Medical Director, West Clinic, discusses his goals for OneOncology

Dr. Schuh, Assistant Professor of Family Medicine, Palliative Medicine, Pharmacy, Mayo Clinic Florida, shares some examples of how supplements are contributing to the use of integrative medicine in cancer care

Jax Zummo, Sr. Director, Corporate Affairs, Lilly Oncology, provides perspective on the rising cost of cancer drugs and patient access

Robin Shah, Chief Development and Chief Marketing Officer, OneOncology, tells us about the impressive capabilities of OneAnalytics

Dr. Schwartzberg, Chief Medical Officer, OneOncology, Medical Director, West Clinic, explains how step therapy and utilization management are impacting community oncology

Dr. Schuh, Assistant Professor of Family Medicine, Palliative Medicine, Pharmacy, Mayo Clinic Florida, describes integrative medicine and how is it applied to the care of cancer patients

Dr. Patton, CEO, Tennessee Oncology, President of Physician Services, OneOncology, considers whether OneOncology is open to growth in new markets and whether size will become a key driver of success

Dr. Patel, CEO, Carolina Blood & Cancer Care, VP, Community Oncology Alliance, considers how tele-medicine is changing the way cancer treatment is delivered

Christine Pfaff, RPh, Associate Director of Practice Operations, Zangmeister Cancer Center, describes how introducing a medically-integrated pharmacy improved care at Zangmeister Cancer Center

Dr. Patton, CEO, Tennessee Oncology, President of Physician Services, OneOncology, tells us about the IT platform at OneOncology and how to efficiently leverage data

Dr. Patt, Medical Oncologist, EVP, Texas Oncology, COA Board of Directors, discusses the aggregation taking place in community oncology

Dr. Patel, CEO, Carolina Blood & Cancer Care, VP, Community Oncology Alliance, considers what practices should know about participating in the Oncology Care Model and two-sided risk

Associate Director of Practice Operations, Zangmeister Cancer Center, discusses some of the challenges associated with medically-integrated pharmacies

Dr. Patton, CEO, Tennessee Oncology, President of Physician Services, OneOncology, explains key drivers of success for OneOncology

Dr. Patt, Medical Oncologist, EVP, Texas Oncology, COA Board of Directors, explains why it is important for community oncologists to partner with associations

Dr. Patel, CEO, Carolina Blood & Cancer Care, VP, Community Oncology Alliance, elaborates on how practices can leverage data to stay compliant with OCM and negotiate stronger payer contracts

Christine Pfaff, RPh, Associate Director of Practice Operations, Zangmeister Cancer Center, explains why cancer treatment centers should adopt medically-integrated pharmacies

Dr. Patton, CEO, Tennessee Oncology, President of Physician Services, OneOncology, considers why community oncologists should embrace novel practice models

Dr. Patt, Medical Oncologist, EVP, Texas Oncology, COA Board of Directors, shares important policy updates coming out of the 2019 Community Oncology Alliance Conference

Dr. Patel, CEO, Carolina Blood & Cancer Care, VP, Community Oncology Alliance, provides perspective on the most intriguing novel practice models presented at the 2019 Community Oncology Alliance Conference

Christine Pfaff, RPh, Associate Director of Practice Operations, Zangmeister Cancer Center, shares how COPA is helping community oncology offices manage their dispensing pharmacies

Dr. Patton, CEO, Tennessee Oncology, President of Physician Services, OneOncology, considers some of the important challenges and solutions for community oncology

Dr. Patt, Medical Oncologist, EVP, Texas Oncology, COA Board of Directors, shares some of the important takeaways from the 2019 Community Oncology Alliance Conference

Dr. Patel, CEO, Carolina Blood & Cancer Care, VP, Community Oncology Alliance, discusses keys to success for today's oncology practices

Sonia Oskouei, PharmD, DPLA, VP, Innovation and Solution Development, Premier, Inc., elaborates on the reimbursement challenges facing biosimilars

Sonia Oskouei, PharmD, DPLA, VP, Innovation and Solution Development, Premier, Inc., shares her opinion regarding the future of biosimilars

Ted Okon, Executive Director, Community Oncology Alliance, reflects on past victories for the Community Oncology Alliance and speculates on future progress

Sonia Oskouei, PharmD, DPLA, VP, Innovation and Solution Development, Premier, Inc., outlines the clinical challenges associated with the adoption of biosimilars in the larger oncology marketplace

Ted Okon, Executive Director, Community Oncology Alliance, on what community oncologists should know about the recent PBM hearing and shares his expectations for the meeting

Sonia Oskouei, PharmD, DPLA, VP, Innovation and Solution Development, Premier, Inc., presents the differences between the FDA approval path for biologics and the approval path for biosimilars

Ted Okon, Executive Director, Community Oncology Alliance, regarding the scope of the step therapy and the utilization management concern for community oncologists

Jonathan Levitt, Co-Founding Partner, Frier Levitt, explains how DIR fees are impacting community oncology

Ted Okon, Executive Director, Community Oncology Alliance, considers whether there is a disconnect between policy and the realities of community oncology

Jonathan Levitt, Co-Founding Partner, Frier Levitt, considers how state legislation regarding community oncology has changed

Dr. Frownfelter, Chief Medical Information Officer, Jvion, Inc., considers how artificial intelligence (AI) is bringing about a better understanding of the whole cancer patient

Jonathan Levitt, Co-Founding Partner, Frier Levitt, explains what has happened in the last 6 months with pharmacy benefit managers (PBMs) and state Medicaids

Dr. Frownfelter, Chief Medical Information Officer, Jvion, Inc., outlines some of the hurdles that artificial intelligence (AI) has introduced into clinical practice

Ben Jones, VP, Government Relations, The US Oncology Network, considers recent policy changes of which oncologists should be aware

Dr. Frownfelter, Chief Medical Information Officer, Jvion, Inc., explains how artificial intelligence is enhancing the delivery of cancer care and contributing to value-based care

Ben Jones, VP, Government Relations, The US Oncology Network, offers his opinion on priority policy concerns

Dr. Frownfelter, Chief Medical Information Officer, Jvion, Inc., shares examples of how artificial intelligence is being applied to cancer care

Nicolas Ferreyros, Director of Communications, Community Oncology Alliance, considers the influence of pharmacy benefit managers on the lives of cancer patients

Dr. Klein, Senior Director, Healthcare Quality Strategy, Strategic Customer Group, Johnson & Johnson Health Care Systems Inc., on embracing value-based oncology care

Nicolas Ferreyros, Director of Communications, Community Oncology Alliance, offers opinion on what medical oncologists and practice administrators should know about communicating with their federal policymakers

Dr. Klein, Senior Director, Healthcare Quality Strategy, Strategic Customer Group, Johnson & Johnson Health Care Systems Inc., provides perspective on the rising cost of cancer drugs and patient access

Nicolas Ferreyros, Director of Communications, Community Oncology Alliance, explains why oncologists should communicate with their local representatives

Dr. Klein, Senior Director, Healthcare Quality Strategy, Strategic Customer Group, Johnson & Johnson Health Care Systems Inc., how value plays a part in cancer drug development

Dr. Johnson, Associate Director, Lung Cancer Research Program, Sarah Cannon Research Institute, shares her thoughts on biomarker development in managing patients with non-small cell lung cancer (NSCLC)

Dr. Johnson, Associate Director, Lung Cancer Research Program, Sarah Cannon Research Institute, tells us about some of the exciting new developments in the treatment of non-small cell lung cancer (NSCLC)

Dr. Jain, Radiation Oncologist, COA Board Member, tells us what physicians and payers should know about proton therapy

Dr. Johnson, Associate Director, Lung Cancer Research Program, Sarah Cannon Research Institute, elaborates on the recent updates to NCCN guidelines regarding PD-L1 testing

Dr. Jain, Radiation Oncologist, COA Board Member, explains the current controversy over the use of proton therapy in cancer care

Dr. Johnson, Associate Director, Lung Cancer Research Program, Sarah Cannon Research Institute, considers the recent data investigating atezolizumab in small cell lung cancer (SCLC)

Dr. Jain, Radiation Oncologist, COA Board Member, explains why proton therapy is important in terms of delivery and outcomes

Robert E. Baird, Jr., RN, MSA, CASC, CEO, Dayton Physicians Network, shares how the Community Oncology Alliance helped Dayton Physicians Network thrive in today’s oncology landscape

Dr. Hall, Radiation Oncologist, Miami Cancer Institute, tells us what physicians and payers should know about proton therapy

Robert E. Baird, Jr., RN, MSA, CASC, CEO, Dayton Physicians Network, shares key takeaways from the 2019 COA Annual Conference

Dr. Hall, Radiation Oncologist, Miami Cancer Institute, explains the current controversy over the use of proton therapy as a cancer therapy

Dr. Aggarwal, Medical Oncologist, OCM Lead, Fort Wayne Medical Oncology and Hematology, COA Board of Directors, explains why transparency is necessary in the healthcare system

Dr. Hall, Radiation Oncologist, Miami Cancer Institute, discusses the difference between photon therapy and proton therapy in terms of delivery and outcomes

Dr. Aggarwal, Medical Oncologist, OCM Lead, Fort Wayne Medical Oncology and Hematology, COA Board of Directors, explains the role of politics in oncology

Dr. Gordan, Managing Physician/President, Florida Cancer Specialists, shares how the shift in site of care is impacting community oncology

Dr. Aggarwal, Medical Oncologist, OCM Lead, Fort Wayne Medical Oncology and Hematology, COA Board of Directors, provides her perspective on the way oncology has evolved, the responsibility of each cancer stakeholder, and the need for transparency

Dr. Gordan, Managing Physician/President, Florida Cancer Specialists, explains how practices should leverage their OCM performance data

Jesse Dresser, Partner, Frier Levitt, evaluates the impact of payer trends and policies on drug manufacturers' market access strategy

Dr. Gordan, Managing Physician/President, Florida Cancer Specialists, offers his opinion on best practices for community oncologists delivering value-based care

Jesse Dresser, Partner, Frier Levitt, tells us what legal tools are available to dispensing oncology practices and pharmacies

Dr. Gordan, Managing Physician/President, Florida Cancer Specialists, discusses primary drivers of the cost of cancer care

Jesse Dresser, Partner, Frier Levitt, elaborates on the major challenges for dispensing oncology practices regarding payer networks

Kathy Gaughran, Senior Marketing Strategist, Healthcare Success, explains how Healthcare Success helps community oncologists increase their patient base

Jesse Dresser, Partner, Frier Levitt, considers some of the trends he is witnessing between payers and dispensing practices and pharmacies

Bobbi Buell, MBA, Principal, Reimbursement and Patient Access Products, onPoint Oncology, on what she understands to be the biggest changes and challenges in medical oncology reimbursement in 2019

Dr. Blau, President & CEO, Quality Cancer Care Alliance (QCCAN) Network, Northwest Medical Specialties, on the pros and cons associated with participation in a clinically integrated network

Sean Brusky, Sr. Director, Oncology Portfolio Partnering, Genentech Inc., explains how the pharmaceutical industry is working to help community oncology thrive

Dr. Blau, President & CEO, Quality Cancer Care Alliance (QCCAN) Network, Northwest Medical Specialties, considers whether clinically integrated networks are positioned as a good model for community practices

Sean Brusky, Sr. Director, Oncology Portfolio Partnering, Genentech Inc., provides Genentech’s perspective on the rising cost of cancer drugs and patient access

Dr. Blau, President & CEO, Quality Cancer Care Alliance (QCCAN) Network, Northwest Medical Specialties, tells us more about IQ Oncology and what they are doing for community oncology practices

Sean Brusky, Sr. Director, Oncology Portfolio Partnering, Genentech, Inc. on taking value into consideration when developing cancer drugs

Dr. Blau, President & CEO, Quality Cancer Care Alliance (QCCAN) Network, Northwest Medical Specialties, explains what the Quality Cancer Care Alliance Network (QCCAN) is doing for participating members

Dr. Diaz, President, Community Oncology Alliance, Florida Cancer Specialists, explains how community oncology is shaping the future of cancer care through clinical trials

Dr. Diaz, President, Community Oncology Alliance, Florida Cancer Specialists, discusses high priority policy initiatives for COA

Dr. Diaz, President, Community Oncology Alliance, Florida Cancer Specialists, considers how COA has evolved over the last few years and articulates his goals for the coming year as president

Dr. Diaz, President, Community Oncology Alliance, Florida Cancer Specialists, tells us what is exciting about the 2019 Community Oncology Conference

Dr. Schleicher, Medical Oncologist, Tennessee Oncology, offers his opinion on entering into a two-sided risk model

Dr. Schleicher, Medical Oncologist, Tennessee Oncology, elaborates on how participating in the Oncology Care Model differs from participating in other alternative payment models

Dr. Schleicher, Medical Oncologist, Tennessee Oncology, explains the challenges associated with value-based care

Dr. Hamrick, Senior Medical Director, Flatiron Health, offers opinion on how practicing oncologists and the FDA could utilize real world evidence

Dr. Hamrick, Senior Medical Director, Flatiron Health, shares how real world evidence figures into clinical trial design

Dr. Hamrick, Senior Medical Director, Flatiron Health, defines and elaborates on the importance of real world evidence

Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, elaborates on what COA and COPA are doing to help practices treat their patients at the point of care

Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, considers the success of COA in helping practices keep their in-office dispensing in network

Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, explains how PBMs are impacting in-office dispensing for oncology practices

Ted Okon, MBA, Executive Director, Community Oncology Alliance, tells us what can be done to encourage transparency at PBMs

Ted Okon, MBA, Executive Director, Community Oncology Alliance, elaborates on what COA is doing to help community oncology practices

Ted Okon, MBA, Executive Director, Community Oncology Alliance, discusses the key issues faced by community oncologists today

Ted Okon, MBA, Executive Director, Community Oncology Alliance, discusses details of the Practice Impact Report released at COA 2018

Ted Okon, MBA, Executive Director, Community Oncology Alliance, discusses the future of 340B policy

Ted Okon, MBA, Executive Director, Community Oncology Alliance, considers whether the reduction in reimbursement for hospitals participating in 340B has changed anything for community oncology

Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, provides perspective on biosimilar pricing and reimbursement

Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, shares which biosimilars are currently approved or close to approval for cancer patients

Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, speculates on what might influence the adoption of biosimilars by oncologists

Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, considers how extrapolation and interchangeability impact the use of biosimilars for cancer patients

Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, discusses what the regulatory pathway looks like for gaining FDA approval of a biosimilar

Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, elaborates on the key features of biosimilars

Rebecca A. Kirch, JD, Executive Vice President, healthcare Quality & Value, National Patient Advocate Foundation, tells us how CMS and commercial insurers have embraced palliative care

Rebecca A. Kirch, JD, Executive Vice President, healthcare Quality & Value, National Patient Advocate Foundation, describes what factors should be considered when starting a cancer patient on a palliative care program

Rebecca A. Kirch, JD, Executive Vice President, healthcare Quality & Value, National Patient Advocate Foundation, explains how a high quality palliative care program impacts quality and clinical outcomes for cancer patients

Dr. Page, President & Director of Research, The Center for Cancer & Blood Disorders, offers opinion on what everyday oncology practices should be doing to advocate on behalf of their patients

Dr. Page, President & Director of Research, The Center for Cancer & Blood Disorders, discusses cancer patient advocacy and the impact on delivery of cancer care

Nate Brown, Senior Product Marketing Manager, Flatiron Health, on whether practices already in a MIPS track should consider moving to an alternative payment model (APM)

Nate Brown, Senior Product Marketing Manager, Flatiron Health, describes how MIPS might look to oncology practices in the future

Nate Brown, Senior Product Marketing Manager, Flatiron Health, discusses how a practice not already participating in MIPS can get started

Nate Brown, Senior Product Marketing Manager, Flatiron Health, provides opinion on why practices should participate in MIPS and not necessarily OCM

Dr. Atkins, Practicing Physician, Augusta Oncology Associates, Board of Directors, COA, Member at Large, Executive Committee, COA, Medical Co-Chair, CPAN, regarding what cancer patients can do to advocate for themselves and each other

Dr. Atkins, Practicing Physician, Augusta Oncology Associates, Board of Directors, COA, Member at Large, Executive Committee, COA, Medical Co-Chair, CPAN, discusses what COA is doing to educate patients on how to get involved in their care and the benefits of receiving treatment in their local area

Dr. Kolodziej, Vice President & Chief Innovation Officer, ADVI, tells us what legislative issues community oncologists should be most concerned about today

Dr. Kolodziej, Vice President & Chief Innovation Officer, ADVI, offers opinion on how the move from volume to value is impacting community oncology

Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, shares some of the cost containment strategies that work best in value-based insurance design

Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, elaborates on whether newer, more expensive cancer therapies impact value-based insurance design and how to design incentives when dealing with these expensive therapies

Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, discusses the challenges associated with value-based insurance design when applied to cancer care

Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, shares examples of value-based insurance design in oncology care

Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, tells us about the motivation behind value-based insurance design

Dr. Diaz, Director of Patient Advocacy, Florida Cancer Specialists, VP, Community Oncology Alliance, offers opinion on what PBMs can do to help community oncology practices

Dr. Diaz, Director of Patient Advocacy, Florida Cancer Specialists, VP, Community Oncology Alliance, describes what cancer patients can do to advocate for themselves

Dr. Diaz, Director of Patient Advocacy, Florida Cancer Specialists, VP, Community Oncology Alliance, elaborates on what COA is doing to educate cancer patients on the care that their practices deliver

Dr. Diaz, Director of Patient Advocacy, Florida Cancer Specialists, VP, Community Oncology Alliance, shares details from the patient initiative on Capital Hill at COA 2018

Kathy Oubre, Chief Operating Officer, Pontchartrain Cancer Center, provides examples of how lobbying has helped move the community oncology agenda forward

Kathy Oubre, Chief Operating Officer, Pontchartrain Cancer Center, elaborates on some of the lobbying tactics that community oncology practices should embrace

Kathy Oubre, Chief Operating Officer, Pontchartrain Cancer Center, discusses why community oncology practices should participate in lobbying

Jonathan E. Levitt, Esq., Founding Partner, Frier Levitt, elaborates on why oncology practices should be aware of co-pay aggregators

Jonathan E. Levitt, Esq., Founding Partner, Frier Levitt, explains how PBM transparency could strengthen the relationship with oncology providers

Jonathan E. Levitt, Esq., Founding Partner, Frier Levitt, elaborates on the problems associated with PBMs, oncology providers and their practices

Jonathan E. Levitt, Esq., Founding Partner, Frier Levitt, analyzes the oncology landscape from a legal perspective

Jeff Mortier, Partner, Farragut Partners, tells us why PBM transparency is so important and what can be done to encourage transparency moving forward

Jeff Mortier, Partner, Farragut Partners, discusses the possible path forward for 340B policy

Jeff Mortier, Partner, Farragut Partners, provides opinion on whether 340B is still having a negative impact on community oncology and whether the rate of reimbursement has been reduced

Jeff Mortier, Partner, Farragut Partners, provides an overview of some of the issues presented at Hill Day at COA 2018

Dr. Schnell, Medical Director, COA, discusses OCM 2.0 and how it is different from OCM 1.0

Dr. Schnell, Medical Director, COA, discusses what COA is doing to help practices succeed in the Oncology Care Model (OCM)

Dr. Schnell, Medical Director, COA, offers opinion on why oncology practice transformation can be so difficult

Dr. Patt, Vice President, Texas Oncology, Board of Directors, COA, elaborates on the recent advances in next-generation sequencing

Dr. Patt, Vice President, Texas Oncology, Board of Directors, COA, shares her perspective on the reimbursement and coverage of CAR-T therapies in the community oncology setting

Dr. Patt, Vice President, Texas Oncology, Board of Directors, COA, offers opinion on what community oncologists should know before prescribing CAR-T therapies

Dr. Patt, Vice President, Texas Oncology, Board of Directors, COA, discusses some of the benefits and challenges community oncologists face when prescribing CAR-T therapy to cancer patients

Dr. Patt, Vice President, Texas Oncology, Board of Directors, COA, offers opinion on how the logistics associated with CAR-T therapies might play out in the community oncology setting

Dr. Patt, Vice President, Texas Oncology, Board of Directors, COA, explains how the broad National Coverage Determination, regarding next-generation sequencing, issued by CMS in March 2018 is helping diagnose and treat cancer patients

Dr. Patt, Vice President, Texas Oncology, Board of Directors, COA, speculates on the availability, reliability and practicality of next-generation sequencing for community oncologists

Dr. Patt, Vice President, Texas Oncology, Board of Directors, COA, tells us about the progress being made in next-generation sequencing and how to use/interpret the results

Dr. Pierce, Practicing Physician, Oregon Oncology Specialists (Salem, OR), Board of Directors, COA, tells us how his practice has evolved with the changing oncology landscape today

Dr. Pierce, Practicing Physician, Oregon Oncology Specialists (Salem, OR), Board of Directors, COA, elaborates on the work his practice is doing to alleviate financial toxicity impacting cancer patients

Dr. Pierce, Practicing Physician, Oregon Oncology Specialists (Salem, OR), Board of Directors, COA, speculates on how to strengthen the doctor-patient relationship in spite of all the hurdles in today’s oncology landscape

Brian DeLashmutt, DeLashmutt Government Relations, explains how the cost of care differs between hospital-based treatment and treatment delivered in the community oncology setting

Brian DeLashmutt, DeLashmutt Government Relations, tells us about his cancer diagnosis, where he was treated and how the care differed between the two sites of care

Dr. Holmes, Attending Physician, Texas Oncology, elaborates on the reimbursement and coverage of CAR-T therapies in the community oncology setting

Dr. Holmes, Attending Physician, Texas Oncology, offers opinion on what community oncologists need to know before prescribing CAR-T therapies in the community and outlines concerns with this site of care

Dr. Holmes, Attending Physician, Texas Oncology, outlines the various benefits and challenges community oncologists face when prescribing CAR-T therapy to patients

Dr. Holmes, Attending Physician, Texas Oncology, considers how the logistics associated with CAR-T therapies could play out in community oncology practices

Suanne Gersdorf, Chief Executive Officer, Oklahoma Cancer Specialists & Research Institute, shares thoughts on how patients have been impacted by value-based care and what her practice is doing to ease financial toxicity

Suanne Gersdorf, Chief Executive Officer, Oklahoma Cancer Specialists & Research Institute, discusses how 340B has affected her organization and speculates on the future for practices

Suanne Gersdorf, Chief Executive Officer, Oklahoma Cancer Specialists & Research Institute, provides examples of how electronic health record (EHR) data can improve quality and/or cost outcomes

Suanne Gersdorf, Chief Executive Officer, Oklahoma Cancer Specialists & Research Institute, elaborates on how practices have become more efficient when utilizing advanced practice nurses (APNs)

Suanne Gersdorf, Chief Executive Officer, Oklahoma Cancer Specialists & Research Institute, explains why it is important for oncology practices to embrace advanced practice nurses (APNs)

Dr. Barnes, Alabama Oncology Hematology Associates, Montgomery Cancer Center, Past President, COA, shares thoughts on how it benefits physicians to train advanced practitioners

Dr. Barnes, Alabama Oncology Hematology Associates, Montgomery Cancer Center, Past President, COA, describes who advanced care providers are and their role in cancer patient care

Dr. Johnson, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute, on how the recent National Coverage Determination for Next Generation Sequencing is relevant to the treatment of NSCLC

Dr. Johnson, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute, discusses combinations and the treatment of lung cancer

Dr. Johnson, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute, on whether a checkpoint inhibitor should be prescribed to newly diagnosed lung cancer patients that have a PD-L1 expression that is less than 1%

Dr. Johnson, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute, discusses stratifying newly diagnosed lung cancer patients with the PD-L1 biomarker

Dr. Johnson, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute, clarifies how physicians should use the PD-L1 biomarker when prescribing checkpoint inhibitors for lung cancer

Dr. Burris, President, Clinical Operations, Sarah Cannon, considers liquid biopsies and their role in cancer care

Dr. Gordan, Florida Cancer Specialists and Research Institute, describes his concerns with PBMs as they affect community oncology practices

Ray Bailey, RPh, Pharmacy Director, Rx To Go, Florida Cancer Specialists, elaborates on the novel approaches to adherence FCS has developed to help patients stay on their oral cancer agents

Ray Bailey, RPh, Pharmacy Director, Rx To Go, Florida Cancer Specialists, shares how he works with payers to make sure his practice can dispense oral cancer agents to patients

Dr. Eagle, Past President, Community Oncology Alliance, Lake Norman Oncology, describes how his small practice manages to thrive in today’s oncology environment

Dr. Eagle, Past President, Community Oncology Alliance, Lake Norman Oncology, examines the rate of oncology spending compared to the total rate of healthcare spending

Dr. Eagle, Past President, Community Oncology Alliance, Lake Norman Oncology, focuses on the amount of drug spending in total oncology care spending

Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, on the advantages and disadvantages of a Professional Services Agreement (PSA) or choosing full employment with the hospital setting

Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, describes his experience working with patients in the hospital outpatient setting versus the community practice setting

Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, comments on how quality of care can change when cancer care moves from the community setting to the hospital setting

Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, discusses the business arrangements available to community oncologists who are considering a closer working relationship with their local hospital system

Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, shares the evolution of his practice toward the current business arrangement with St. Francis Health System in Tulsa, OK

Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, comments on why independent community oncology practices join a hospital system

Dr. Green, Senior Vice President, Clinical Oncology, Flatiron Health, recommends how oncologists should leverage data to better utilize claims data

Bobbi Buell, Code Mistress, onPoint Oncology, offers advice to practices to assure good coding

Bobbi Buell, Code Mistress, onPoint Oncology, elaborates on the implications of mistakes in coding

Dr. Cobb, Medical Director, St. Vincent Frontier Cancer Center, explains how moving to a hospital outpatient setting has changed the quality of cancer care at St. Vincent Frontier Cancer Center

Dr. Cobb, Medical Director, St. Vincent Frontier Cancer Center, comments on how clinical trials are able to help physicians take better care of patients and contribute to a revenue stream

Dr. Burris, President, Clinical Operations, Sarah Cannon, offers insight into how clinical pathways impact prescribing decisions

Dr. Burris, President, Clinical Operations, Sarah Cannon, considers the role of oral oncolytics in the treatment of cancer patients

Dr. Burris, President, Clinical Operations, Sarah Cannon, comments on the impact of OCM on large community practices and, specifically, those with high participation rate in clinical trials

Dr. Feinberg, VP Medical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, sheds light on some of the ways Cardinal Health is impacting and changing the world of oncology

Dr. Feinberg, VP Medical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses his current area of interest in the world of oncology

Dr. Feinberg, VP Medical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, offers his opinion on site of care and its ultimate impact on cancer economics

Dr. Feinberg, VP Medical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, offers recommendations for community oncologists when thinking about MACRA, MIP’s and OCM

Dr. Patton, Chief Executive Officer, Tennessee Oncology, discusses how clinical pathways are helping with value-based efforts at Tennessee Oncology

Dr. Patton, Chief Executive Officer, Tennessee Oncology, shares his thoughts on the impact of oral cancer agents on practice economics

Dr. Patton, Chief Executive Officer, Tennessee Oncology, discusses the impact of OCM on the prescribing of oral cancer agents

Dr. Patton, Chief Executive Officer, Tennessee Oncology, elaborates on how a large practice like Tennessee Oncology, with the associated financial risk, manages the transition to value-based care

Dr. Patton, Chief Executive Officer, Tennessee Oncology, outlines the “four pillars” Tennessee Oncology has adopted as a result of participation in OCM

Dr. Gordan, Florida Cancer Specialists and Research Institute, discusses how 340B has impacted the physicians and practices in his geography

Robert Baird Jr., RN, MSA, CASC, Chief Executive Officer, Dayton Physicians Network, elaborates on how his practice has been forging relationships with other cancer stakeholders to benefit care delivery

Robert Baird Jr., RN, MSA, CASC, Chief Executive Officer, Dayton Physicians Network, shares a few of the most significant changes at his practice as a result of OCM

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, elaborates on whether clinical pathways are achieving their original promise of improving outcomes and reducing cost while maintaining quality

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, discusses how pathways have impacted oncology treatment over the last five years

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, offers his opinion on whether medical oncologists and patients should be comfortable using biosimilars in oncology

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, discusses oncology targeting biosimilars that are nearing approval

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, describes the legal challenges surrounding biosimilars and market entry

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, discusses the status of the biosimilars regulatory pathway

Ted Okon, Executive Director, Community Oncology Alliance, provides highlights from the COA 2017 Community Oncology Conference

Ted Okon, Executive Director, Community Oncology Alliance, outlines the impact PBMs have on oncologists and cancer patients

Ted Okon, Executive Director, Community Oncology Alliance, discusses the latest on the 340B policy in Washington, D.C.

Ben Jones, Vice President, Government Relations and Public Policy, McKesson Specialty Health, addresses health care provides and practices that want to get involved in advocating for community oncology

Ben Jones, Vice President, Government Relations and Public Policy, McKesson Specialty Health, details what McKesson Specialty Health is doing to help community oncologists succeed today

Ben Jones, Vice President, Government Relations and Public Policy, McKesson Specialty Health, offers his thoughts on the hot policy topics that are impacting the delivery of quality cancer care today

Dr. Wilfong, Director of Quality Programs for Texas Oncology; Physician Champion for OCM at McKesson Specialty Health, explains what practices not participating in OCM can learn from his experience

Dr. Wilfong, Director of Quality Programs for Texas Oncology; Physician Champion for OCM at McKesson Specialty Health, shares how OCM is affecting the cancer patients in his practice

Dr. Wilfong, Director of Quality Programs for Texas Oncology; Physician Champion for OCM at McKesson Specialty Health, reveals how OCM is changing his practice

Dr. Patt, MPH, MBA, Vice President, Texas Oncology, on how community oncology has contributed and advanced clinical research

Dr. Patt, MPH, MBA, Vice President, Texas Oncology, discusses how technological advances in cancer care have been advanced by community oncology

Dr. Patt, MPH, MBA, Vice President, Texas Oncology, reveals how community oncology has contributed to advances in population health

Dr. Patt, MPH, MBA, Vice President, Texas Oncology, lists the ways community oncology contributes to the Cancer Moonshot

Dr. Atkins, Medical Oncologist, Augusta Oncology Associates, shares an example of how patients and the COA Patient Advocacy Network can make a difference

Dr. Atkins, Medical Oncologist, Augusta Oncology Associates, describes how community oncologists can get their patients involved in the COA Patient Advocacy Network

Dr. Atkins, Medical Oncologist, Augusta Oncology Associates, lists the goals of the COA Patient Advocacy Network and how the organization is benefitting cancer patients

Dr. Vacirca, President, Community Oncology Alliance, CEO, New York Cancer Specialists, describes the efforts of COA to address DIR fees coming from PBMs

Dr. Vacirca, President, Community Oncology Alliance, CEO, New York Cancer Specialists, shares with community oncologists across the country what he wants them to know about COA’s efforts to represent them

Dr. Vacirca, President, Community Oncology Alliance, CEO, New York Cancer Specialists, details the scope of the problem with DIR fees and how COA hopes to work with Congress to solve the PBM fee problem

Dr. Vacirca, President, Community Oncology Alliance, CEO, New York Cancer Specialists, elaborates on what COA is doing to help resolve the Part B concerns of community oncologists

Dr. Hamrick, Medical Oncologists, Senior Medical Director, Flatiron Health, shares how the EMR can solve quality reporting challenges and improve work flow efficiency

Dr. Hamrick, Medical Oncologists, Senior Medical Director, Flatiron Health, shares his opinion on how physicians can be more efficient in their work flow

Dr. Hamrick, Medical Oncologists, Senior Medical Director, Flatiron Health, offers his recommendation for practices to manage unstructured data in order to succeed in value-based care

Dr. Gordan, Florida Cancer Specialists and Research Institute, shares his thoughts on how practices can improve participation in clinical trials, and how they can turn clinical trials into a revenue stream

Dr. Gordan, Florida Cancer Specialists and Research Institute, debriefs community oncology practices on how to utilize their own data to negotiate and improve outcomes with payers

Dr. Gordan, Florida Cancer Specialists and Research Institute, on how he envisions community oncology utilizing big data

Matt Farber, Senior Director, Oncology Disease State, Walgreen Co, explains how specialty pharmacies work with payers to help deliver cancer care

Matt Farber, Senior Director, Oncology Disease State, Walgreen Co, on whether all specialty pharmacies are the same and are associated with a PBM

Matt Farber, Senior Director, Oncology Disease State, Walgreen Co, explains how specialty pharmacies are evolving to meet the unique needs of community oncology practices

Matt Farber, Senior Director, Oncology Disease State, Walgreen Co, describes the role specialty pharmacy plays in delivering quality cancer care

Dr. Burris, President, Clinical Operations, Sarah Cannon, on whether or not it is worth the time and expense to search for rare mutations

Dr. Eagle, Past President, Community Oncology Alliance, Lake Norman Oncology, explains how operating in a small community oncology practice differs from working in a large practice or in a hospital setting

Ray Bailey, RPh, Pharmacy Director, Rx To Go, Florida Cancer Specialists, provides insight into how participation in OCM impacts the in-house pharmacy at FSC

Bobbi Buell, Code Mistress, onPoint Oncology, shares the most common mistakes in billing, and how practices can overcome these mistakes

Dr. Burris, President, Clinical Operations, Sarah Cannon, on whether or not clinicians should continue to molecular profile patients with the immunotherapies available today

Dr. Cobb, Medical Director, St. Vincent Frontier Cancer Center, explains the difference in cost of cancer care between the hospital outpatient setting and the community setting

Brad Prechtl, MBA, Chief Executive Officer of Florida Cancer Specialists, on whether or not size matters when it comes to community oncology practices

Brad Prechtl, MBA, Chief Executive Officer of Florida Cancer Specialists, elaborates on how “shared savings” works between Florida Cancer Specialists and a local payer

Brad Prechtl, MBA, Chief Executive Officer of Florida Cancer Specialists, offers his opinion on the keys to success for FCS

Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, shares how clinical pathways impact treatment decisions at FCS

Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, offers insight into how FCS aggregate all the quality measures required for OCM

Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, elaborates on how FCS is working with local payers to deliver quality care while reducing costs

Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, shares how FCS has evolved since participating in OCM

Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, explains the transition from fee for service to value-based care at FCS

Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, discusses 1 sided and 2 sided risk associated with participation in the OCM

Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, shares her concerns with the way OCM is progressing at this point

Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, on what she would like to accomplish if she became president of the AMA

Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, discusses what the AMA is doing to help all physicians working in all practice settings

Ricky Newton, CPA, Director of Financial Services & Operations, COA, provides an example of how a PBM is impacting cancer patient care

Ricky Newton, CPA, Director of Financial Services & Operations, COA, describes the paper COA is releasing at this year’s meeting on patient experiences with PBMs

Ricky Newton, CPA, Director of Financial Services & Operations, COA, tells us how COA is addressing the PBM DIR fees and helping community oncology

Ricky Newton, CPA, Director of Financial Services & Operations, COA, describes what happened with CVS last year and how COPA is working with CVS today

Dr. Green, Senior Vice President, Clinical Oncology, Flatiron Health, on how oncologists can leverage data to understand real quality care

Dr. Green, Senior Vice President, Clinical Oncology, Flatiron Health, explains how he defines big data

Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, explains how the AMA and community oncology should interact

Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, discusses novel payer initiatives she finds interesting

Charles Bane, MD, Oncologist, President, Dayton Physicians Network touches on the COME HOME project while discussing the Oncology Care Model

Charles Bane, MD, Oncologist, President, Dayton Physicians Network touches on the COME HOME project while discussing the Oncology Care Model

Charles Bane, MD, Oncologist, President, Dayton Physicians Network discusses the practicality of the value tool at Dayton Physicians Network

Perspective on the NCCN Evidence Blocks by Charles Bane, MD, Oncologist, President, Dayton Physicians Network

Perspective on the ASCO Value Framework by Charles Bane, MD, Oncologist, President, Dayton Physicians Network

Bruce Gould, MD, President and Medical Director, Northwest Georgia Medical Centers explains how the value tools could be used in the community practice setting

Perspective on the NCCN Evidence Blocks provided by Bruce Gould, MD, President and Medical Director, Northwest Georgia Medical Centers

Perspective on the ASCO Value Framework provided by Bruce Gould, MD, President and Medical Director, Northwest Georgia Medical Centers

Bruce Gould, MD, President and Medical Director, Northwest Georgia Medical Centers, explains ASCO’s policy toward clinical pathways at this time

The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD, President and Medical Director, Northwest Georgia Medical Centers

Bruce Gould, MD, President and Medical Director, Northwest Georgia Medical Centers, describes the concerns his practice has with clinical pathways

Barbara McAneny, MD, CEO, New Mexico Cancer Center & Innovative Oncology Business Solutions, explains why CMS implemented the ASP experiment

Barbara McAneny, MD, CEO, New Mexico Cancer Center & Innovative Oncology Business Solutions, informs as to what practices should know about MACRA

Barbara McAneny, MD, CEO, New Mexico Cancer Center & Innovative Oncology Business Solutions, reviews the COME HOME project’s influence on the Oncology Care Model

Barbara McAneny, MD, CEO, New Mexico Cancer Center & Innovative Oncology Business Solutions, discusses COME HOME’s adaptability to other community oncology practices

Barbara McAneny, MD, CEO, New Mexico Cancer Center & Innovative Oncology Business Solutions, talks about the COME HOME project’s impact on other community oncology practices

Barbara McAneny, MD, CEO, New Mexico Cancer Center & Innovative Oncology Business Solutions, discusses the COME HOME project’s future

Jeff Patton, MD, CEO, Tennessee Oncology, explains what could happen if the CMS ASP Experiment proceeds as planned by CMS

The reasons to become a member and support the Community Oncology Alliance (COA) as demonstrated by Tennessee Oncology and spoken to by Jeff Patton, MD, CEO, Tennessee Oncology

Jeff Patton, MD, CEO, Tennessee Oncology, explains why the 2016 Community Oncology Alliance (COA) meeting is a must attend meeting

Jeff Patton, MD, CEO, Tennessee Oncology, discusses his new role with the Community Oncology Alliance (COA)

Deborah Patt, MD, MPH, MBA, VP, Policy, Director of Public Policy, Texas Oncology, shares her concerns about the CMS ASP Experiment and Part B reimbursement

Deborah Patt, MD, MPH, MBA, VP, Policy, Director of Public Policy, Texas Oncology, tells us how chemotherapy costs figure into total care

Deborah Patt, MD, MPH, MBA, VP, Policy, Director of Public Policy, Texas Oncology, points out how oncologists can reduce cancer costs

Deborah Patt, MD, MPH, MBA, VP, Policy, Director of Public Policy, Texas Oncology, details surprising outcomes from a recent cost study

Deborah Patt, MD, MPH, MBA, VP, Policy, Director of Public Policy, Texas Oncology, looks at the bigger expense drivers in cancer care

David Eagle, MD, Past President, COA, Physician, Lake Norman Oncology, gives his opinion on the CMS ASP Experiment

David Eagle, MD, Past President, COA, Physician, Lake Norman Oncology, enumerates what oncologists can do to bring cancer costs down

David Eagle, MD, Past President, COA, Physician, Lake Norman Oncology, lists outcomes from the COA study surprising to oncologists

David Eagle, MD, Past President, COA, Physician, Lake Norman Oncology, details the bigger expenses driving up cancer care costs based on the COA study

David Eagle, MD, Past President, COA, Physician, Lake Norman Oncology, compares costs for treating cancer vs. non-cancer based on the COA study

David Eagle, MD, Past President, COA, Physician, Lake Norman Oncology, talks about COA’s Cost Drivers of Cancer Care study

Bhuvana Sagar, MD, National Medical Director, Cigna Healthcare, tells us about the Cigna medical home for oncologists

Bhuvana Sagar, MD, National Medical Director, Cigna Healthcare, discusses Cigna’s work with oncologists to find alternative payment models

Bhuvana Sagar, MD, National Medical Director, Cigna Healthcare, explains the need for alternative payment models in oncology

Barry Russo, CEO, The Center for Cancer & Blood Disorders, explains the impact of the CMS ASP Experiment

Practices need to get ready to replace buy and bill explains Barry Russo, CEO, The Center for Cancer & Blood Disorders

Bruce Gould, MD, President and Medical Director, Northwest Georgia Oncology Centers, explains the characteristics of a practice that can participate in the Oncology Care Model

Brad Prechtl, MBA, CEO, Florida Cancer Specialists, briefs us on his concerns with the“Medicare Experiment” and its impact

Brad Prechtl, MBA, CEO, Florida Cancer Specialists, tells how his practice is working to improve cancer care

Brad Prechtl, MBA, CEO, Florida Cancer Specialists, talks about how community oncology practices can survive today

Brad Prechtl, MBA, CEO, Florida Cancer Specialists, explains the benefits of community oncology practices joining forces

Bhuvana Sagar, MD, National Medical Director, Cigna Healthcare, forecasts the possible Cigna adoption of a Medicare OCM model

Participation in the Oncology Care Model (OCM) as explained by Barry Russo, CEO, The Center for Cancer & Blood Disorders

Barry Russo, CEO, The Center for Cancer & Blood Disorders, explains how important it is to embrace alternative payment models

Barry Russo, CEO, The Center for Cancer & Blood Disorders, tells us how his practice is getting ready for value-based care

Patrick Cobb, MD, FACP, Medical Director, St. Vincent Frontier Cancer Center, looks ahead to treatment innovations that will make a difference for patients

Patrick Cobb, MD, FACP, Medical Director, St. Vincent Frontier Cancer Center, talks about some exciting, recent innovations in cancer treatment

Michael Diaz, MD, Director of Advocacy, Florida Cancer Specialists, COA Secretary, talks about working with payers to add quality and value

Michael Diaz, MD, Director of Advocacy, Florida Cancer Specialists, COA Secretary, discusses the challenges in adopting quality and value measures

Michael Diaz, MD, Director of Advocacy, Florida Cancer Specialists, COA Secretary, talks about why the community oncology setting represents the best value for cancer patients

John Fox, MD, AVP, Priority Health, predicts if the ASCO Value Framework or NCCN Evidence Blocks will eventually impact drug spend

John Fox, MD, AVP, Priority Health, talks about how Priority might use the ASCO and NCCN value tools

John Fox, MD, AVP, Priority Health, talks about the new value tools from ASCO and NCCN

John Fox, MD, AVP, Priority Health, provides perspective on collaborating with providers on clinical pathways

A look at cancer clinical pathways with Charles Bane, MD, Oncologist, President, Dayton Physicians Network

Ricky Newton, CPA, Director of Financial Services & Operations, COA, updates us on COPA

Ricky Newton, CPA, Director of Financial Services & Operations, COA, details how COPA’s website is helping practice managers, pharmacists, and patients

Ricky Newton, CPA, explains the purpose of COPA’s new In-House and Specialty Pharmacies brief

Ricky Newton, CPA, Director of Financial Services & Operations, COA, tells us what follow up to expect from COPA’s new brief

Robert Baird, CEO, fills us in on the Value-Based Purchasing Modifier‘s impact on Dayton

Robert Baird, CEO, details how practices can prepare for the Value-Based Purchasing Modifier and MIPS

Robert Baird, CEO, explains how Dayton physicians and payers are collaborating on APMs

Robert Baird, CEO, answers questions on Dayton’s participation in the Oncology Care Model

Skip Burris, MD, President, Clinical Operations, Sarah Cannon Research Institute, outlines the scope of cancer clinical trials at SCRI

Skip Burris, MD, President, Clinical Operations, Sarah Cannon Research Institute, talks about how CAR-Ts work, and the trials taking place at SCRI

Skip Burris, MD, President, Clinical Operations, Sarah Cannon Research Institute, looks at the promise of immunotherapies in combination

Skip Burris, MD, President, Clinical Operations, Sarah Cannon Research Institute, explains goals and outcomes of the My Pathway trial

Skip Burris, MD, President, Clinical Operations, Sarah Cannon Research Institute, reflects on the promise and concerns with liquid biopsies

Ted Okon, Executive Director, Community Oncology Alliance (COA), tells us why the CNS ASP Experiment is a bad idea

Embrace alternative payment models explains Ted Okon, Executive Director, Community Oncology Alliance (COA)

Todd Murphree, PharmD, Dispensing Pharmacy Manager, Clearview Cancer Institute, tells us how in-house dispensing in his practice benefits patients

Todd Murphree, PharmD, Dispensing Pharmacy Manager, Clearview Cancer Institute, tells us how in-house dispensing in his practice benefits patients

Todd Murphree, PharmD, Dispensing Pharmacy Manager, Clearview Cancer Institute, explains the role an in-house pharmacy plays in the quality equation

Sue Naeyaert, Senior Director at EMD Serono, predicts whether we will see more cancer biosimilars soon

So far the approved biosimilars haven’t been much of a price reduction, Sue Naeyaert, Senior Director of EMD Serono, tells us what to expect in pricing biosimilars

A look at the expansion of a biosimilar’s FDA label with Sue Naeyaert, Senior Director at EMD Serono

Sue Naeyaert, Senior Director at EMD Serono, explains the proposed reimbursement of biosimilars by CMS

Skip Burris, MD, President, Clinical Operations, Sarah Cannon Research Institute, discusses how precision medicine is changing cancer treatment

Sue Naeyaert, Senior Director at EMD Serono, provides her vision of the biosimilar products in development for the treatment of cancer

Todd Murphree, PharmD, Dispensing Pharmacy Manager, Clearview Cancer Institute, briefs us on ACHC’s oncology accreditation process

Todd Murphree, PharmD, Dispensing Pharmacy Manager, Clearview Cancer Institute, discusses how ACHC accreditation benefits his practice

Ted Okon, Executive Director, Community Oncology Alliance (COA), discusses the sessions that stand out at this year's annual meeting

Ted Okon, Executive Director, Community Oncology Alliance (COA), discusses the 2016 Community Oncology Alliance annual meeting

Ted Okon, Executive Director, Community Oncology Alliance (COA), discusses the 2016 Community Oncology Alliance annual meeting

Ted Okon, Executive Director, Community Oncology Alliance (COA), provides an overview of the Cost Drivers in Cancer Care study

Mary Kruczynski, Director of Policy Analysis, COA, speaks to those who were unable to attend the 2016 Annual COA meeting

Mary Kruczynski, Director of Policy Analysis, COA tells us how the 2016 Annual COA meeting benefits health care providers

Mary Kruczynski, Director of Policy Analysis, COA, reflects on highlights from COA

Lucio Gordan, MD, Medical Oncologist, Florida Cancer Specialists, lists takeaways from COA that can benefit his own practice

Lucio Gordan, MD, Medical Oncologist, Florida Cancer Specialists, debriefs providers who didn’t attend on highlights from COA

Lucio Gordan, MD, Medical Oncologist, Florida Cancer Specialists, reflects on key messages from this year’s COA

Jeff Vacirca, MD, CEO, Managing Partner, NSHOA Cancer Center, explains the relevance of the COA/Milliman study to his practice

Jeff Vacirca, MD, CEO, Managing Partner, NSHOA Cancer Center, talks about what his community oncology practice is doing to survive

Working with private payers is just one way Tennessee Oncology is embracing alternative payment models according to Jeff Patton, MD, CEO, Tennessee Oncology

The Community Oncology Alliance (COA) is helping community oncologists by fighting the CMS ASP Experiment by Jeff Patton, MD, CEO, Tennessee Oncology

Robert Baird, CEO, tells us what MIPS are and how practices might use them

Patrick Cobb, MD, FACP, Medical Director, St. Vincent Frontier Cancer Center, discusses treatment innovations and managing patient’s expectations

Jeff Vacirca, MD, CEO, Managing Partner, NSHOA Cancer Center, shares his thoughts on the effect of the “Medicare Experiment” on community oncology

David Eagle, MD, Past President, COA, Physician, Lake Norman Oncology, compares treatment costs in the hospital outpatient setting and the community practice

Mary Kruczynski tells us how the Cost Drivers in Cancer Care study was developed and presented at the 2016 Annual COA meeting

Dr. Beer, Chief Medical Officer, OSHU Knight Cancer Institute, discusses relugolix, the newly FDA approved oral GNRH antagonist for prostate cancer

Dr. Coleman, Chief Scientific Officer, US Oncology Network, discusses significance of the 2 recent FDA approvals for PARP inhibitors in ovarian cancer

Dr. Rifkin, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, on whether medical oncologists are adopting therapeutic biosimilars in treatment algorithms

Dr. Abraham provides perspective on biosimilar pricing and reimbursement

Dr. Abraham describes the potential hurdles that might prevent the adoption of biosimilars by oncologists

Dr. Abraham discusses some of the key characteristics of a biosimilar

Dr. Goldberg, Medical Director, West Virginia University Cancer Institute, provides opinion on the new FDA indication for pembrolizumab in tumor-agnostic MSI-high patients